Immune and Cell Therapy in Non-Hodgkin Lymphoma - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Cancer Journal Année : 2020

Immune and Cell Therapy in Non-Hodgkin Lymphoma

Résumé

The promise of immunotherapy has shone brightly for decades in hematologic malignancies and specifically in non-Hodgkin lymphoma. The last decade has witnessed the emergence of completely novel forms of immunotherapy, including immune checkpoint blockade, bispecific antibodies, and chimeric antigen receptor T cells. These treatments have shown phenomenal, and in some cases possibly curative, successes in various relapsed/refractory lymphomas. This review summarizes the most notable successes and promising findings as well as some of the attendant failures. These treatments will doubtlessly transform the treatment paradigms across many lymphoma subtypes. Yet, only if we can better understand their mechanisms of action, toxicity, and resistance will be able to maximize their therapeutic benefit.

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-02890214 , version 1 (06-07-2020)

Identifiants

Citer

Reid W. Merryman, Roch Houot, Philippe Armand, Caron Jacobson. Immune and Cell Therapy in Non-Hodgkin Lymphoma. Cancer Journal, 2020, 26 (3), pp.269-277. ⟨10.1097/PPO.0000000000000445⟩. ⟨hal-02890214⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More